Corient Private Wealth
GMAB icon

Corient Private Wealth’s Genmab GMAB Stock Holding History

Corient Private Wealth’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$448K Sell
16,297
-350
-2% -$9.3K ﹤0.01% 2300
2026
Q1 		$436K Sell
16,647
-822
-5% -$24.6K ﹤0.01% 2104
2025
Q4 		$538K Buy
17,469
+1,724
+11% +$53.7K ﹤0.01% 1831
2025
Q3 		$483K Buy
+15,745
New +$384K ﹤0.01% 1808
2025
Q2 		– Sell
-20,548
Closed -$402K – 2482
2025
Q1 		$402K Buy
+20,548
New +$431K ﹤0.01% 1705
2024
Q4 		– Sell
-10,505
Closed -$256K – 2418
2024
Q3 		$256K Buy
10,505
+22
+0.2% +$588 ﹤0.01% 2092
2024
Q2 		$263K Buy
+10,483
New +$297K ﹤0.01% 1983
2023
Q4 		– Sell
-9,020
Closed -$318K – 2283
2023
Q3 		$318K Buy
9,020
+595
+7% +$22.7K ﹤0.01% 1728
2023
Q2 		$320K Buy
8,425
+293
+4% +$11.7K ﹤0.01% 1665
2023
Q1 		$307K Buy
+8,132
New +$313K ﹤0.01% 1596

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Corient Private Wealth's GMAB Position: Q2 2026 in Review

Corient Private Wealth reduced its Genmab (GMAB) stake by 2.1% in Q2 2026, selling an estimated $9.3K and leaving 16,297 shares worth $448K. The position accounts for ﹤0.01% of the portfolio, ranked #2300.

Corient Private Wealth first reported a position in GMAB in Q1 2023 and has held it in 10 quarters since. The position peaked at $538K in Q4 2025. 291 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Corient Private Wealth held 16,297 shares of Genmab worth $448K as of Q2 2026.
  • Corient Private Wealth sold 350 Genmab shares in Q2 2026, an estimated $9.3K.
  • Genmab made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2300 holding.
  • Corient Private Wealth first reported a position in Genmab in Q1 2023 and has held it in 10 quarters since.
  • Corient Private Wealth's Genmab position peaked at $538K in Q4 2025.
  • 291 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.